Extraintestinal Entamoeba Histolytica Amebiasis
Executive Summary
Extraintestinal amebiasis is a clinical disease caused by the protozoan Entamoeba histolytica spreading beyond the intestines. While most E. histolytica infections are asymptomatic, invasive disease can manifest as amebic dysentery or, more critically, as extraintestinal infections.
The primary and most common extraintestinal manifestation is the amebic liver abscess (ALA), a significant cause of mortality from parasitic infections worldwide, with an estimated 50,000 deaths annually. The disease predominantly affects adult males (7 to 10 times more than other groups), especially in the fourth and fifth decades of life, and is most frequently seen in migrants from or travelers to endemic regions such as India, Africa, Mexico, and parts of Central and South America.
The classic clinical presentation of ALA involves one to two weeks of fever and right upper quadrant (RUQ) pain. Diagnosis is established through a combination of relevant epidemiology, clinical findings, radiographic imaging (ultrasound, CT, or MRI), and confirmation with serologic tests, which are highly sensitive.
Treatment is highly effective and involves a two-pronged approach: a tissue agent, such as metronidazole or tinidazole, to treat the invasive disease, followed by a luminal agent, such as paromomycin, to eradicate the intraluminal cysts and prevent relapse. Drainage of the abscess is not routinely required but may be warranted in specific high-risk scenarios.
Rarer but severe extraintestinal manifestations can occur, typically resulting from the rupture of a liver abscess into adjacent structures. These include pleuropulmonary amebiasis (affecting 20-35% of ALA cases), and much rarer cardiac, brain, and cutaneous involvement, each carrying significant morbidity and mortality.
1. Introduction and Pathogenesis
Extraintestinal amebiasis is caused by the protozoan parasite Entamoeba histolytica. The infection begins in the intestine, and while most cases remain asymptomatic, the parasite can invade tissue, leading to either amebic dysentery or extraintestinal disease. Amebae establish hepatic infection by ascending the portal venous system from the colon.
The factors that predispose an individual to progress from intestinal infection to an amebic liver abscess are not fully understood. However, evidence suggests several contributing factors:
Genetic Strains: Different genetic strains of E. histolytica may be morphologically identical but vary in their likelihood to cause specific clinical manifestations.
Host Immunity: Conditions that affect cell-mediated immunity, such as immunosuppression associated with HIV infection, may increase the chance of E. histolytica causing invasive disease with liver involvement.
2. Amebic Liver Abscess (ALA): The Primary Manifestation
Amebic liver abscess is the most common extraintestinal manifestation of amebiasis and the fourth leading cause of mortality from any parasitic infection globally.
2.1. Epidemiology and Risk Factors
Demographics: The disease is 7 to 10 times more common in adult males than in other demographic groups. It is most frequently observed in individuals in their fourth and fifth decades of life.
Geographic Association: In developed nations, amebiasis is generally seen in migrants and travelers returning from endemic areas, including India, Africa, Mexico, and parts of Central and South America.
Exposure: While associated with travel, amebic liver abscesses are relatively uncommon among short-term travelers. However, they can occur after exposures as short as four days. One study noted that 35 percent of travelers with ALA had spent less than six weeks in an endemic region.
Transmission: Sexual oral-anal contact is a known mode of acquisition. Infections can also occur, though rarely, in individuals in nonendemic areas who have never traveled abroad.
2.2. Clinical Presentation
Onset: The typical presentation occurs 8 to 20 weeks (median 12 weeks) after a patient returns from an endemic area. However, the interval can be much longer, with reports of onset occurring years or even decades after exposure.
Core Symptoms: The most common symptoms are fever (typically 38.5 to 39.5°C) and right upper quadrant (RUQ) pain, which are usually present for one to two weeks before the patient seeks care. The pain may be dull, aching, or pleuritic and can refer to the epigastrium, right chest, or right shoulder.
Associated Symptoms: Other potential symptoms include cough, sweating, malaise, weight loss, anorexia, and hiccough.
Gastrointestinal Symptoms: Concurrent diarrhea is present in less than one-third of patients, although some report a history of dysentery within the preceding few months.
Physical Examination: Findings frequently include hepatomegaly and point tenderness over the liver, which are present in approximately 50 percent of cases. Jaundice is uncommon, occurring in less than 10 percent of patients.
2.3. Complications
The most significant complication of ALA is rupture of the abscess into an adjacent space or organ.
Thoracic Extension: Rupture into the chest is nearly four times more common than extension into the peritoneal cavity.
Peritoneal Extension: Rupture into the peritoneum, causing peritonitis, occurs in up to 7 percent of cases.
Other Complications: Rare but serious complications that have been described include hepatic aneurysm, active hemorrhage, and thrombosis of the inferior vena cava or hepatic vein due to inflammation and mechanical compression.
2.4. Prognosis
Uncomplicated Cases: The mortality rate for an uncomplicated amebic liver abscess that is diagnosed and treated early is less than 1 percent.
Increased Risk: In one study from India involving 135 patients, the overall mortality rate was 17 percent. Independent risk factors for increased mortality included:
Bilirubin level >3.5 mg/dL
Serum albumin <2.0 g/dL
Large volume of the abscess cavity
Presence of multiple abscesses
Encephalopathy
3. Diagnosis of Amebic Liver Abscess
The diagnosis of ALA relies on a combination of clinical suspicion, laboratory tests, imaging, and confirmatory serology or antigen testing.
3.1. Laboratory Findings
Complete Blood Count: Leukocytosis (>10,000/mm³) without eosinophilia is a common finding.
Liver Function Tests: An elevated alkaline phosphatase is seen in 80 percent of cases. Hepatic transaminases may also be elevated.
3.2. Imaging
Radiographic imaging is a cornerstone of diagnosis and can be performed with ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI).
Lesion Characteristics: Amebic liver abscesses are typically solitary (70-80 percent of cases) and subcapsular. Lesions in the left lobe predispose to extension into the pericardial sac.
Ultrasound: Appears as a round, well-defined hypoechoic mass. The image may show a peripheral solid part with a central liquefied portion containing low-level internal echoes.
CT Scan: Appears as a low-density mass, often with a peripheral enhancing rim.
MRI: Shows low-signal intensity on T1-weighted images and high-signal intensity on T2-weighted images.
Chest Radiograph: Abnormalities are seen in approximately 50 percent of patients, with the most common finding being an elevation of the right hemidiaphragm. This does not necessarily indicate direct pulmonary involvement.
3.3. Serology and Antigen Detection
Antibody Tests: The most common confirmatory test is an immunoglobulin (Ig)G enzyme-linked immunosorbent assay (ELISA).
Sensitivity: Serologic tests are highly sensitive. Detectable antibodies are present in 92 to 97 percent of patients at the time of presentation and develop in approximately 99 percent of patients with ALA. Testing may be negative during the first seven days of illness.
Specificity in Endemic Areas: In endemic regions, a positive serology may reflect a past infection. Therefore, a negative serology is more useful for excluding the disease than a positive test is for confirming it.
3.4. Aspiration and Drainage
Needle aspiration or catheter drainage is not routinely required for diagnosis or treatment but may be warranted in specific situations:
The cyst is large (>10 cm in diameter).
There is an imminent risk of rupture (particularly for lesions in the left lobe).
The patient shows clinical deterioration or lacks a response to empiric therapy.
Exclusion of alternative diagnoses (e.g., pyogenic abscess) is necessary.
When performed, the aspirated fluid classically has an "anchovy paste" appearance—a thick, brown fluid consisting of acellular, proteinaceous debris and necrotic hepatocytes. Trophozoites are seen on microscopy in fewer than 20 percent of aspirates. Antigen testing or PCR on the aspirated material offers higher diagnostic sensitivity (75 to 100 percent).
4. Differential Diagnosis
ALA must be distinguished from other causes of focal liver lesions, primarily pyogenic liver abscess, echinococcal disease, and malignancy.
5. Treatment and Management
5.1. General Approach
In cases where ALA is suspected based on epidemiology, clinical findings, and imaging, empiric treatment should be initiated. The standard of care is a two-drug regimen targeting both the invasive tissue parasites and the intraluminal cysts.
5.2. Tissue Agents
These drugs target the invasive trophozoites in the liver and other tissues.
Primary Agents:
Metronidazole: 500 to 750 mg orally three times daily for 7 to 10 days.
Tinidazole: 2 g orally once daily for 5 days.
Efficacy: The cure rate with these agents is over 90 percent.
Alternatives: Other options include ornidazole and nitazoxanide.
5.3. Luminal Agents
Following treatment for invasive amebiasis, a luminal agent is required to eliminate intraluminal cysts, even if stool microscopy is negative, to prevent relapse.
Recommended Agents:
Paromomycin: 25 to 30 mg/kg per day orally in three divided doses for 7 days.
Diloxanide furoate: 500 mg orally three times daily for 10 days.
Diodoquin (iodoquinol): 650 mg orally three times daily for 20 days.
5.4. Management in Pregnancy
Amebic liver abscess during pregnancy can cause significant morbidity and mortality.
Favored Treatment: Metronidazole is the favored agent. While it crosses the placenta, its use is considered justified in cases of severe illness.
Alternative: Chloroquine (600 mg base daily for two days, followed by 300 mg base daily for three weeks) is an acceptable alternative.
Luminal Treatment: Pregnant women should subsequently receive paromomycin to eliminate intraluminal cysts.
6. Other Extraintestinal Manifestations
While ALA is the most common, E. histolytica can rarely cause disease in other sites, often as a complication of ALA.
6.1. Pleuropulmonary Amebiasis
Prevalence: Occurs in 20 to 35 percent of patients with ALA, typically from the rupture of a liver abscess.
Manifestations: Can present as a sympathetic serous effusion, an amebic empyema (rupture into the pleural space), or a lung abscess or hepatobronchial fistula (rupture into the lung).
Symptoms: Clinical signs include pain, cough, hemoptysis, and dyspnea. If a fistula develops, the patient may expectorate large amounts of amebic pus, sometimes described as having an "anchovy sauce" appearance.
Diagnosis & Treatment: Diagnosis is made with the same methods as for ALA, with serology being positive in over 90 percent of cases. Treatment involves aspiration of pleural effusions and a course of metronidazole or tinidazole, followed by a luminal agent.
6.2. Cardiac Amebiasis
Pathogenesis: A rare but highly fatal complication, usually resulting from the rupture of a left lobe liver abscess into the pericardium.
Clinical Features: Can lead to acute pericarditis, pericardial tamponade, congestive cardiac failure, or constrictive pericarditis.
Diagnosis: PCR testing on pericardial fluid may be positive for E. histolytica.
6.3. Brain Abscess
Pathogenesis: An extremely rare manifestation resulting from hematogenous spread of the parasite.
Clinical Course: Characterized by an abrupt onset of symptoms and rapid progression to death if left untreated.
Treatment: Requires immediate initiation of metronidazole.
6.4. Cutaneous Amebiasis
Pathogenesis: A rare manifestation that can result from direct inoculation or extension from another site. Perineal cutaneous disease may occur in infants wearing diapers or as a sexually transmitted infection in individuals who practice insertive anal intercourse.
